new warnings about using rosiglitazone (Avandia) in patients with ANY degree of heart failure

September 2006

You'll see new warnings about using rosiglitazone (Avandia) in patients with ANY degree of heart failure.

We already know to avoid giving rosiglitazone or pioglitazone (Actos) to patients with severe heart failure.

Now there's evidence that rosiglitazone increases cardiac risk in patients with LESS severe heart failure.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote